BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

11992

524470

SYNCOMF

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

SYNCOM FORMU (I) LTD performance

Today’s low

Today’s high

₹ 16.25 ₹ 16.89
₹ 16.32

52 week low

52 week high

₹ 10.95 ₹ 27.90
₹ 16.32

Open Price

₹ 16.81

Prev. Close

₹ 16.81

Volume (Shares)

2213456.00

Total traded value

₹ 361.23

Upper Circuit

₹ 20.17

Lower Circuit

₹ 13.44

info

SYNCOM FORMU (I) LTD Share Price Update

As of the latest trading session, SYNCOM FORMU (I) LTD share price is currently at ₹ 16.32, which is down by ₹ -0.48 from its previous closing. Today, the stock has fluctuated between ₹ 16.25 and ₹ 16.89. Over the past year, SYNCOM FORMU (I) LTD has achieved a return of 21.37 %. In the last month alone, the return has been -1.75 %. Read More...

SYNCOM FORMU (I) LTD fundamentals


  • Market cap (Cr)

    1,534.08

  • P/E Ratio (TTM)

    40.98

  • Beta

    1.15

  • Book Value / share

    3.31

  • Return on equity

    8.71%

  • EPS (TTM)

    0.41

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    12.79

info icon alternate text
  • Market cap (Cr)

    1,541.60

  • P/E Ratio (TTM)

    40.98

  • Beta

    1.06

  • Book Value / share

    3.31

  • Return on equity

    8.71%

  • EPS (TTM)

    0.41

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    12.79

info icon alternate text

SYNCOM FORMU (I) LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 127.03
Operating Expense 113.94
Net Profit 12.79
Net Profit Margin (%) 10.06
Earnings Per Share (EPS) 0.14
EBITDA 18.41
Effective Tax Rate (%) 24.31
Particulars SEP 2024 (Values in Cr)
Revenue 101.49
Operating Expense 91.02
Net Profit 10.95
Net Profit Margin (%) 10.78
Earnings Per Share (EPS) 0.16
EBITDA 16.11
Effective Tax Rate (%) 25.25
Particulars JUN 2024 (Values in Cr)
Revenue 85.86
Operating Expense 78.05
Net Profit 7.63
Net Profit Margin (%) 8.88
Earnings Per Share (EPS) 0.11
EBITDA 11.79
Effective Tax Rate (%) 24.45
Particulars MAR 2024 (Values in Cr)
Revenue 73.27
Operating Expense 66.93
Net Profit 6.75
Net Profit Margin (%) 9.21
Earnings Per Share (EPS) 0.09
EBITDA 11.68
Effective Tax Rate (%) 26.71
Particulars DEC 2023 (Values in Cr)
Revenue 63.34
Operating Expense 59.07
Net Profit 6.42
Net Profit Margin (%) 10.13
Earnings Per Share (EPS) 0.09
EBITDA 11.12
Effective Tax Rate (%) 25.34
Particulars MAR 2024 (Values in Cr)
Revenue 258.36
Operating Expense 239.67
Net Profit 23.62
Net Profit Margin (%) 9.14
Earnings Per Share (EPS) 0.32
EBITDA 40.93
Effective Tax Rate (%) 25.62
Particulars MAR 2023 (Values in Cr)
Revenue 224.64
Operating Expense 212.70
Net Profit 20.07
Net Profit Margin (%) 8.93
Earnings Per Share (EPS) 0.20
EBITDA 34.24
Effective Tax Rate (%) 24.46
Particulars MAR 2022 (Values in Cr)
Revenue 219.66
Operating Expense 205.51
Net Profit 19.79
Net Profit Margin (%) 9.00
Earnings Per Share (EPS) 0.26
EBITDA 32.06
Effective Tax Rate (%) 24.40
Particulars MAR 2021 (Values in Cr)
Revenue 244.81
Operating Expense 211.27
Net Profit 29.17
Net Profit Margin (%) 11.91
Earnings Per Share (EPS) 0.38
EBITDA 45.00
Effective Tax Rate (%) 28.32
Particulars MAR 2020 (Values in Cr)
Revenue 205.51
Operating Expense 193.39
Net Profit 14.25
Net Profit Margin (%) 6.93
Earnings Per Share (EPS) 0.17
EBITDA 21.81
Effective Tax Rate (%) 17.58
Particulars MAR 2024 (Values in Cr)
Book Value / Share 3.07
ROE % 9.30
ROCE % 10.91
Total Debt to Total Equity 0.29
EBITDA Margin 16.48
Particulars MAR 2023 (Values in Cr)
Book Value / Share 2.72
ROE % 8.39
ROCE % 9.57
Total Debt to Total Equity 0.29
EBITDA Margin 15.39
Particulars MAR 2022 (Values in Cr)
Book Value / Share 2.52
ROE % 8.91
ROCE % 9.93
Total Debt to Total Equity 0.26
EBITDA Margin 14.59
Particulars MAR 2017 (Values in Cr)
Book Value / Share 1.50
ROE % 9.32
ROCE % 13.22
Total Debt to Total Equity 0.08
EBITDA Margin 10.46
Particulars MAR 2016 (Values in Cr)
Book Value / Share 1.39
ROE % 9.92
ROCE % 14.69
Total Debt to Total Equity 0.06
EBITDA Margin 10.37
Particulars MAR 2024 (Values in Cr)
Book Value / Share 3.05
ROE % 8.71
ROCE % 10.32
Total Debt to Total Equity 0.29
EBITDA Margin 15.94
Particulars MAR 2023 (Values in Cr)
Book Value / Share 2.72
ROE % 8.39
ROCE % 9.57
Total Debt to Total Equity 0.29
EBITDA Margin 15.36
Particulars MAR 2022 (Values in Cr)
Book Value / Share 2.52
ROE % 9.66
ROCE % 10.49
Total Debt to Total Equity 0.29
EBITDA Margin 14.59
Particulars MAR 2021 (Values in Cr)
Book Value / Share 2.25
ROE % 17.51
ROCE % 20.42
Total Debt to Total Equity 0.19
EBITDA Margin 18.47
Particulars MAR 2020 (Values in Cr)
Book Value / Share 1.87
ROE % 10.24
ROCE % 12.18
Total Debt to Total Equity 0.04
EBITDA Margin 10.69
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 67.86
Total Assets 404.66
Total Liabilities 404.66
Total Equity 288.14
Share Outstanding 940000000
Price to Book Ratio 3.67
Return on Assets (%) 6.25
Return on Capital (%) 7.02
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 8.63
Total Assets 377.83
Total Liabilities 377.83
Total Equity 256.01
Share Outstanding 940000000
Price to Book Ratio 2.17
Return on Assets (%) 5.31
Return on Capital (%) 5.92
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.38
Total Assets 308.23
Total Liabilities 308.23
Total Equity 222.22
Share Outstanding 862453000
Price to Book Ratio 4.22
Return on Assets (%) 6.42
Return on Capital (%) 7.07
Particulars MAR 2017 (Values in Cr)
Cash & Short Term Investments 6.51
Total Assets 180.17
Total Liabilities 180.17
Total Equity 117.35
Share Outstanding 780652180
Price to Book Ratio 1.35
Return on Assets (%) 5.84
Return on Capital (%) 8.12
Particulars MAR 2016 (Values in Cr)
Cash & Short Term Investments 5.69
Total Assets 175.40
Total Liabilities 175.40
Total Equity 108.69
Share Outstanding 780652180
Price to Book Ratio 1.60
Return on Assets (%) 5.90
Return on Capital (%) 9.06
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 67.83
Total Assets 391.50
Total Liabilities 391.50
Total Equity 286.45
Share Outstanding 940000000
Price to Book Ratio 3.67
Return on Assets (%) 6.03
Return on Capital (%) 6.6
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 8.57
Total Assets 376.94
Total Liabilities 376.94
Total Equity 256.01
Share Outstanding 940000000
Price to Book Ratio 2.17
Return on Assets (%) 5.32
Return on Capital (%) 5.92
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.38
Total Assets 308.23
Total Liabilities 308.23
Total Equity 222.22
Share Outstanding 862453000
Price to Book Ratio 4.22
Return on Assets (%) 6.42
Return on Capital (%) 7.07
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 64.20
Total Assets 291.64
Total Liabilities 291.64
Total Equity 187.58
Share Outstanding 789952180
Price to Book Ratio 1.38
Return on Assets (%) 10.00
Return on Capital (%) 11.68
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 8.57
Total Assets 180.52
Total Liabilities 180.52
Total Equity 145.65
Share Outstanding 780652180
Price to Book Ratio 0.39
Return on Assets (%) 7.89
Return on Capital (%) 9.64
Particulars MAR 2024 (Values in Cr)
Net Income 33.97
Cash from Operations 2.12
Cash from Investing 83.01
Cash from Financing -14.55
Net change in Cash 62.50
Free Cash Flow 10.26
Particulars MAR 2023 (Values in Cr)
Net Income 26.55
Cash from Operations 17.18
Cash from Investing -44.95
Cash from Financing 35.00
Net change in Cash 0.57
Free Cash Flow 37.81
Particulars MAR 2022 (Values in Cr)
Net Income 26.15
Cash from Operations 22.57
Cash from Investing -27.07
Cash from Financing 8.29
Net change in Cash -2.44
Free Cash Flow 33.88
Particulars MAR 2017 (Values in Cr)
Net Income 15.87
Cash from Operations 17.88
Cash from Investing -17.68
Cash from Financing 4.66
Net change in Cash 0.82
Free Cash Flow 30.78
Particulars MAR 2016 (Values in Cr)
Net Income 16.20
Cash from Operations 29.62
Cash from Investing -22.84
Cash from Financing -2.40
Net change in Cash -1.07
Free Cash Flow 32.90
Particulars MAR 2024 (Values in Cr)
Net Income 31.78
Cash from Operations 1.64
Cash from Investing 83.82
Cash from Financing -15.36
Net change in Cash 62.52
Free Cash Flow 9.78
Particulars MAR 2023 (Values in Cr)
Net Income 26.55
Cash from Operations 17.14
Cash from Investing -44.97
Cash from Financing 35.00
Net change in Cash 0.52
Free Cash Flow 37.77
Particulars MAR 2022 (Values in Cr)
Net Income 26.15
Cash from Operations 22.57
Cash from Investing -27.07
Cash from Financing 8.29
Net change in Cash -2.44
Free Cash Flow 33.88
Particulars MAR 2021 (Values in Cr)
Net Income 40.67
Cash from Operations 9.23
Cash from Investing -75.35
Cash from Financing 71.96
Net change in Cash -5.45
Free Cash Flow 11.89
Particulars MAR 2020 (Values in Cr)
Net Income 17.34
Cash from Operations 10.29
Cash from Investing 1.51
Cash from Financing -6.51
Net change in Cash 0.85
Free Cash Flow 12.04
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 19.95 2.02 284.31 34.11 / 77.70
BLISS GVS PHARMA LTD 122.65 16.07 1.27 1292.37 92.25 / 184.95
CIPLA LTD 1541.00 24.94 4.38 124457.39 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 272.25 22.56 2.76 801.26 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 22.35 6.30 284.31 34.11 / 77.70
AMRUTAJAN HEALTH LTD 679.10 39.81 6.59 1963.32 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8795.90 131.18 32.36 21989.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 122.65 15.93 1.26 1292.37 92.25 / 184.95

SYNCOM FORMU (I) LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
16.32 -2.91 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 17.10
  • 26 Days 17.10
  • 10 Days 17.20
  • 50 Days 17.20
  • 12 Days 17.20
  • 100 Days 17.70
  • 20 Days 17.10
  • 200 Days 17.50
16.89 PIVOT

First Support

16.52

First Resistance

17.18

Second Support

16.23

Second Resistance

17.55

Third Support

15.86

Third Resistance

17.84

RSI

47.26

ADX

12.52

MACD

0.10

Williams % R

-40.77

Commodity Channel Index (CCI)

-38.88

Date

2025-04-29

Week

1071096.00

Same Day

849602.00

Month

983241.00

1 Year

1.16

3 Year

0.92

Over 1 Month

-1.75%

down

Over 1 Year

21.37%

down

Over 3 Months

-4.86%

down

Over 3 Years

27.55%

down

Over 6 Months

-11.75%

down

Over 5 Years

0.00%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

SYNCOM FORMU (I) LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
49.32%
Promoter Holdings
50.56%
FII
0.1%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Kedarmal Shankarlal Bankda 1.1692612E8 (12.44%) Shareholding of Promoter and Promoter Group
Vijay Shankarlal Bankda 9.8554595E7 (10.48%) Shareholding of Promoter and Promoter Group
Paradise Vyapar Private Limited 4.7186125E7 (5.02%) Shareholding of Promoter and Promoter Group
Ankit Bankda 4.688642E7 (4.99%) Shareholding of Promoter and Promoter Group
Asha Vijay Bankda 4.6054319E7 (4.9%) Shareholding of Promoter and Promoter Group
Vimla Bankda 4.005932E7 (4.26%) Shareholding of Promoter and Promoter Group
Strand Developers Pvt. Ltd. 3.5875E7 (3.82%) Shareholding of Promoter and Promoter Group
Vijay Bankda Huf 1.2068E7 (1.28%) Shareholding of Promoter and Promoter Group
Payal Ankur Bankda 1.172016E7 (1.25%) Shareholding of Promoter and Promoter Group
Kedarmal Shankarlal Bankda Huf 1.048404E7 (1.12%) Shareholding of Promoter and Promoter Group
Sulabh Rahul Bankda 9300100.0 (0.99%) Shareholding of Promoter and Promoter Group
Rahul Bankda 169500.0 (0.02%) Shareholding of Promoter and Promoter Group
Ankur Vijay Bankda 63900.0 (0.01%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

SYNCOM FORMU (I) LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
09 Sep 2022 0.03 Final 13 Sep 2022 Equity shares
21 Sep 2017 0.02 Final 23 Sep 2017 Equity shares
22 Sep 2016 0.02 Final 26 Sep 2016 Equity shares
16 Sep 2015 0.02 Final 19 Sep 2015 Equity shares
18 Sep 2014 0.02 Final 20 Sep 2014 Equity shares
10 Jul 2013 0.6 Final 12 Jul 2013 Equity shares
20 Sep 2012 0.6 Final 24 Sep 2012 Equity shares
22 Sep 2011 0.5 Final 26 Sep 2011 Equity shares
23 Sep 2010 0.5 Final 27 Sep 2010 Equity shares
24 Sep 2009 0.5 Final 28 Sep 2009 Equity shares
23 Sep 2008 0.5 Final 25 Sep 2008 Equity shares
20 Sep 2007 1.0 Final 24 Sep 2007 Equity shares
19 Sep 2006 0.0 Final 21 Sep 2006 Equity shares
22 Sep 2005 0.0 Final 26 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
20 Aug 2013 19 Aug 2013 5:2
Ex-Date Old FV NEW FV Record Date
19 Aug 2013 10.0 1.0 20 Aug 2013
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
09 Sep 2022 0.03 Final 13 Sep 2022 Equity shares
21 Sep 2017 0.02 Final 23 Sep 2017 Equity shares
22 Sep 2016 0.02 Final 26 Sep 2016 Equity shares
16 Sep 2015 0.02 Final 19 Sep 2015 Equity shares
18 Sep 2014 0.02 Final 20 Sep 2014 Equity shares
10 Jul 2013 0.6 Final 12 Jul 2013 Equity shares
20 Sep 2012 0.6 Final 24 Sep 2012 Equity shares
22 Sep 2011 0.5 Final 26 Sep 2011 Equity shares
23 Sep 2010 0.5 Final 27 Sep 2010 Equity shares
24 Sep 2009 0.5 Final 28 Sep 2009 Equity shares
23 Sep 2008 0.5 Final 25 Sep 2008 Equity shares
20 Sep 2007 1.0 Final 24 Sep 2007 Equity shares
19 Sep 2006 0.0 Final 21 Sep 2006 Equity shares
22 Sep 2005 0.0 Final 26 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
20 Aug 2013 19 Aug 2013 5:2
Ex-Date Old FV NEW FV Record Date
19 Aug 2013 10.0 1.0 20 Aug 2013

SYNCOM FORMU (I) LTD Share Price

Incorporated as a private limited company in 1988, Syncom Formulations (India) Limited was converted into a public limited company in Jun.'92. The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency. Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh.

Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards. Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers.

The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations. Commercial production commenced in Apr.'89. Promoters are Kedarmal Bankda, Vijay Kumar Bankda and Ajay Kumar Bankda.

In addition to pharmaceutical formulations in the form of tablets, capsules, liquids and dry powders, the company also manufactures injectibles and ear/eye drops on a loan licence basis.

In 1994, the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur, Madhya Pradesh. The project which was financed through a public issue made in Jan.'94 was completed in 1995.

During the year 1997-98, the Company has further diversified into Ethical Operations by introducing the range of prescription formulations.

During the year 1998-99 there has been huge expansion of installed capacity and production base. Further the company plans introduction of products in the generic, OTC and Ethical Divisions. The export earnings have also registered a growth of more than 100%.

During the year 1999-2000, the company and its associates have received export orders worth Rs.700.00 lacs against advance payment and hence better turnover is expected during the year. The company presently exports goods to Guine, Ghana, Kenya, Tanzania, Nigeria in Africa, Azberjan, Nepal and Srilanka in Asia. The company has been approved as a supplier to Central ESI Hospitals and registration of defence services is in its final stages, as a result of which will generate substantial sales volume. Keeping in view the shifting consumer preferenes for the use of herbal products, the company is aggressively manufacturing and marketing its herbal products like Edicare, Attom Megacaps, Ecziguard and Yas antacid salt.

The modernisation of injectable section by putting Tunnel System and other modern equipments and expansion of tablet department by
putting high speed mega press machines was completed in 2002. The Company carried out an expansion program of the installed
capacities of its manufacturing unit at Pithampur, Dist. Dhar to increase the capacity of tablet section by 35% and also doubling of the
capacity of capsule section. Capacity of packing section was increased in line with the increase in capacity of the said formulation
sections. The expansion cum modernization program was implemented at a total cost of Rs. 1.34 crore out of which the major expenditure was incurred in 2002-03. The expanded capacities were made available for production from May, 2003.

In 2007, the Company launched a new division 'Cratus Life Care' to expand its operations. The expansion cum modernization project at Pithampur unit was completed with the total investment costing Rs 15.17 Crore during the year 2007-08. The Company raised long term financial resources by way of preference issuance of 3,10,000 equity shares of Rs.10 each at a premium of Rs.36 per share on 29 March, 2008 to the promoters of the Company and the said Equity got listed with the BSE in 2008.

In 2020-21, the business activity of the Company was expanded by increasing the overall production capacity of Injectable capacity from 200 Lakhs to 300 Lakhs per annum and to modernize the Tablet Department within an overall cost of Rs. 4031.50 Lakhs which
was funded by the issuance of fresh share capital to meet the overall cost of the project.

Parent organization Indian Private
NSE symbol SYNCOMF
Founded 1988
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Syncom Formulations (India) Ltd?

Answer Field

The share price of Syncom Formulations (India) Ltd for NSE is ₹ 16.32 and for BSE is ₹ 16.4.

What is the Market Cap of Syncom Formulations (India) Ltd?

Answer Field

The market cap of Syncom Formulations (India) Ltd for NSE is ₹ 15,34.08 Cr. and for BSE is ₹ 15,41.60 Cr. as of now.

What is the 52 Week High and Low of Syncom Formulations (India) Ltd?

Answer Field

The 52 Week High and Low of Syncom Formulations (India) Ltd for NSE is ₹ 27.90 and ₹ 10.95 and for BSE is ₹ 27.94 and ₹ 11.00.

How to Buy Syncom Formulations (India) Ltd share?

Answer Field

You can trade in Syncom Formulations (India) Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Syncom Formulations (India) Ltd?

Answer Field

The 1 year returns on the stock has been 21.37%.

What is the Current Share Price of Syncom Formulations (India) Ltd?

Answer Field

Syncom Formulations (India) Ltd share price is for NSE ₹ 16.32 & for BSE ₹ 16.4 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Syncom Formulations (India) Ltd Share?

Answer Field

The market cap of Syncom Formulations (India) Ltd for NSE ₹ 15,34.08 & for BSE ₹ 15,41.60 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Syncom Formulations (India) Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Syncom Formulations (India) Ltd share is 40.98.

What is the PB ratio of Syncom Formulations (India) Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Syncom Formulations (India) Ltd share is 3.31.

How to Buy Syncom Formulations (India) Ltd Share?

Answer Field

You can trade in Syncom Formulations (India) Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Syncom Formulations (India) Ltd Share on Bajaj Broking App?

Answer Field

To buy Syncom Formulations (India) Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Syncom Formulations (India) Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|